Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.